Best known as the company that launched the world’s first “antibody biosimilar,” Celltrion is looking to continue its growth as a global biopharmaceutical company. Its general manager for Turkey, SeokHoon Kang and commercial director, Mahmut Uyar, outline the Korean company’s strong performance in 2020, how they are leveraging their commercial and manufacturing presence in Turkey, and the strategy to expand their portfolio, which currently consists of three approved products in the country.
Celltrion is a true pioneer in biosimilars. Our objective at the moment is to launch at least one product per year; we try to be very competitive in the biosimilar market considering our leading position
